Interview with Niranjan Kulkarni, Senior Director, Allan Bream, Process Specialist, and Grace Linton, Process Architect at CRB that originally appeared in Cell and Gene Therapy Insights, on how commercial biopharma experience is shaping cell and gene therapy facility design.
Cell therapies are emerging as an important class of next-generation medicines. As many novel treatments move through development to commercialization, manufacturers are challenged to construct optimal facilities for the production of cell therapies. Modeling and simulation at the earliest design stages have many benefits.
Building information modeling software improves efficiency.
Technology, like BIM, is changing more than just healthcare’s latest therapeutic modalities and pharmaceutical advances. It’s also disrupting the design and implementation of the facilities that create them.
Water for injection (WFI) is used in the pharmaceutical industry to formulate parenteral drugs and for cleaning and other manufacturing operations. Reverse osmosis followed by a polishing step can be a more efficient and cost-effective solution for WFI production.
Advanced therapy medicinal product (ATMP) companies are ushering in a new frontier of medicine and technologies poised to revolutionize human health, but are ATMP facilities keeping up? The industry is advancing at such a rapid pace that these companies are faced with vast new complexities when developing and manufacturing their products.